DYN
Dyne Therapeutics, Inc.Company Information
- Company Name
- Dyne Therapeutics, Inc.
- CIK
- CIK0001818794
- Category
- Large accelerated filer
- Ticker: Exchange
- DYN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- DYN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-08
- Last sale
- 2026-09-08
- Shares purchased (TTM)
- 16,000
- Shares sold (TTM)
- 4,658,898
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 156,638,240
- Shares outstanding
- 165,670,880
- Ownership
- 94.55%
Earnings Market Reaction
- Filing date
- 2026-07-29
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 676 | 753 | 893 | 574 | 485 | 472 | 435 | 532 | 608 | 272 | 122 | 130 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 938 | 1,021 | 1,127 | 806 | 698 | 690 | 659 | 736 | 792 | 488 | 129 | 168 | ||||||
| Available For Sale Securities Debt Securities Current | 222 | 219 | 217 | 218 | 199 | 205 | 207 | 192 | 171 | 182 | 1 | 28 | ||||||
| Prepaid Expense And Other Assets Current | 39 | 49 | 16 | 14 | 14 | 12 | 17 | 13 | 13 | 35 | 6 | 10 | ||||||
| Property Plant And Equipment Net | 25 | 24 | 24 | 24 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Operating Lease Right Of Use Asset | 20 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | ||||||
| Assets | 994 | 1,080 | 1,187 | 867 | 729 | 721 | 691 | 769 | 826 | 522 | 165 | 205 | ||||||
Liabilities | ||||||||||||||||||
| Accounts Payable Current | 12 | 11 | 8 | 12 | 14 | 7 | 7 | 6 | 2 | 7 | 23 | 4 | ||||||
| Accrued Liabilities And Other Liabilities | 46 | 29 | 38 | 43 | 22 | 22 | 31 | 32 | 23 | 10 | 23 | 21 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 78 | 51 | 51 | 60 | 41 | 34 | 42 | 43 | 30 | 22 | 51 | 30 | ||||||
| Operating Lease Liability Current | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Long Term Debt | 199 | 149 | 149 | 99 | 99 | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 15 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | ||||||
| Liabilities | 292 | 215 | 215 | 175 | 158 | 52 | 61 | 63 | 51 | 44 | 74 | 53 | ||||||
| Preferred Stock Value | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 2,398 | 2,382 | 2,368 | 1,975 | 1,747 | 1,734 | 1,580 | 1,565 | 1,539 | 1,176 | 724 | 718 | ||||||
| Stockholders Equity | 702 | 865 | 972 | 692 | 571 | 669 | 630 | 706 | 775 | 478 | 91 | 152 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,696 | -1,517 | -1,396 | -1,284 | -1,176 | -1,065 | -950 | -860 | -763 | -698 | -633 | -566 | ||||||
| Liabilities And Stockholders Equity | 994 | 1,080 | 1,187 | 867 | 729 | 721 | 691 | 769 | 826 | 522 | 165 | 205 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 166 | 165 | 165 | 143 | 114 | 114 | 102 | 102 | 100 | 87 | 61 | 61 | ||||||
| Shares Outstanding | 166 | 165 | 165 | 143 | 114 | 114 | 102 | 102 | 100 | 87 | 61 | 61 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialDyne Therapeutics, Inc. (DYN) — SEC Financial Statements & Analysis
Dyne Therapeutics, Inc. (DYN) is a pharmaceutical preparations company, incorporated in DE. Dyne Therapeutics, Inc. trades on Nasdaq as: DYN. Dyne Therapeutics, Inc. (DYN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-29. Based on that filing, Dyne Therapeutics, Inc. carries a market cap of $3.68B, a P/E ratio of -7.08x, a P/B ratio of 5.24x, an enterprise value of $3.20B, and an EV/EBITDA multiple of -5.99x. On profitability, it posts a Return on Equity (ROE) of -81.57%, a Return on Assets (ROA) of -60.29%, and a Return on Invested Capital (ROIC) of -261.56%. Per share, it reports EPS of $-3.14, free cash flow per share of $-2.90, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 25.80% year-over-year and EPS growth of -13.18% year-over-year. On the balance sheet, it maintains a current ratio of 12.02x, a quick ratio of 11.51x, working capital of $859.86M, a debt-to-equity ratio of 0.42x, a debt ratio of 0.29, free cash flow of $-480.43M (TTM), and net debt of $-476.79M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.68B
- P/E TTM
- -7.08x
- EPS TTM
- $-3.14
- P/B TTM
- 5.24x
- ROE TTM
- -81.57%
- ROA TTM
- -60.29%
- Debt To Equity
- 0.42x
- Free Cash Flow TTM
- $-480.43M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Dyne Therapeutics, Inc. in?
Dyne Therapeutics, Inc. (DYN) operates in the Pharmaceutical Preparations industry.
What exchange does DYN trade on?
Dyne Therapeutics, Inc. (DYN) trades on the Nasdaq.
Where is Dyne Therapeutics, Inc. incorporated?
Dyne Therapeutics, Inc. is incorporated in DE.
When was Dyne Therapeutics, Inc. (DYN)'s most recent SEC filing?
Dyne Therapeutics, Inc. (DYN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-29.
What is DYN's market cap?
Dyne Therapeutics, Inc. (DYN) has a market capitalization of $3.68B as of 2026-06-30.
What is DYN's EPS (earnings per share)?
Dyne Therapeutics, Inc. (DYN)'s trailing twelve month EPS is $-3.14 as of 2026-06-30.
What is DYN's ROE (return on equity)?
Dyne Therapeutics, Inc. (DYN)'s trailing twelve month Return on Equity (ROE) is -81.57% as of 2026-06-30.
What is DYN's ROA (return on assets)?
Dyne Therapeutics, Inc. (DYN)'s trailing twelve month Return on Assets (ROA) is -60.29% as of 2026-06-30.
What is DYN's ROIC (return on invested capital)?
Dyne Therapeutics, Inc. (DYN)'s trailing twelve month Return on Invested Capital (ROIC) is -261.56% as of 2026-06-30.
What is DYN's EV/EBITDA?
Dyne Therapeutics, Inc. (DYN)'s trailing twelve month EV/EBITDA is -5.99x as of 2026-06-30.